Regis Healthcare vs Ryman Healthcare shares: Which ASX small cap has more upside?
Investors on the hunt for turnaround potential in the aged care sector might be weighing up Regis Healthcare Ltd (ASX: REG) and Ryman Healthcare Ltd (ASX: RYM) shares. Both are well-known operators in residential aged care and retirement living, but each tells a different story when it comes to valuation, dividends, and recent momentum. If you’re searching for which beaten down small cap has the better shot at a true bounce-back, here’s how the fundamentals stack up.
The case for Regis Healthcare
Regis Healthcare is a major player in Australian aged care, chiefly focused on residential aged care services. Apart from its core aged care facilities, Regis also offers retirement villages, home care, and a variety of day therapy and respite programs. Founded in 1994 and based in Melbourne, Regis has built a strong reputation for providing specialist care for seniors across the country.
A few fundamentals stand out. Regis Healthcare currently sports a market cap of $1.39 billion and a P/E ratio of 24.86. While that’s not rock-bottom, it could be seen as fair given the sector. Notably, the company has delivered a fully franked dividend yield of 4.03%, which is quite attractive for income-minded investors. YTD, though, the shares have underperformed, with a painful -31.6% return. Recent dividends have bounced back to 100% franking, after a spell of partial franking in earlier yearsâa positive for those relying on franking credits.
The case for Ryman Healthcare
Ryman Healthcare is a New Zealand-headquartered provider of integrated retirement living, with operations in both New Zealand and Australia. Ryman develops and manages large retirement villages, offering everything from independent living through to rest home, hospital, and dementia care. Ryman’s model has long emphasised a full spectrum of care, designed to let residents “age in place”.
Looking at the fundamentals, Ryman is slightly larger by market cap ($1.50 billion), but it’s currently in tougher financial shape. There’s no P/E ratio available, and the latest reported EPS is negative (-0.615), suggesting it’s running at a loss. The year to date return is even bleaker than Regis: the shares have fallen -42.4%. Ryman hasn’t paid a dividend according to the available data, and there’s no info on franking, reinforcing its current focus on stabilising the business rather than rewarding shareholders.
Valuation comparison
There’s a notable divergence in how the market is pricing these two aged care shares, particularly when it comes to earnings and yield.
| Metric | Regis Healthcare | Ryman Healthcare |
|---|---|---|
| Market Cap | $1.39 billion | $1.50 billion |
| P/E Ratio | 24.86 | N/A |
| Earnings per Share (EPS) | $0.184 | -$0.615 |
| Dividend Yield | 4.03% (100% franked) | 0.00% |
| Year to Date Return | -31.60% | -42.38% |
Regis is profitable, offering a fully franked yield, while Ryman is loss-making and not paying dividends at all. Note: Ryman Healthcare’s reported P/E ratio is “N/A” because its latest earnings are negative.
Recent share price momentum
Comparing recent share price performance up to 16 October 2026:
- As of 16 October 2026, Regis Healthcare closed at $4.50, having shown some intraday recovery recently but down heavily over the year.
- As of 16 October 2026, Ryman Healthcare finished at $1.47, reflecting its own volatility, but with a steeper annual decline than Regis.
- Year to date, Regis is down -31.6%, while Ryman has fallen -42.4%.
Both stocks have experienced significant downward momentum this year. However, Ryman has fallen from a higher base and lost a greater percentage of its value.
Which is the better buy?
For investors looking for a beaten-down small cap with true “double from the bottom” potential, I’d lean toward Regis Healthcare. Here’s why: Regis remains profitable, pays a fully franked dividend, and maintains a clear pathway to recovery if operating conditions stabilise. Yes, its P/E is higher than value hunters might like, and its 31.6% share price fall is roughâyet it’s still generating earnings and rewarding shareholders today.
Ryman Healthcare, on the other hand, is battling through losses, has suspended its dividend, and its shares have fallen even further. While deep turnarounds can deliver outsized rewards, I think the additional uncertainty and the lack of ongoing income tilt the risk/reward too far for my taste.
In short, although both companies look deeply out of favour right now, if I were betting on which could double from here, my pick would be Regis Healthcare. Its underlying profitability, dividend history, and Australian market exposure give me more confidence in a rebound from current levels.
The post Regis Healthcare vs Ryman Healthcare: Which under-the-radar ASX small-cap could double from here? appeared first on The Motley Fool Australia.
Wondering where to invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right nowâ¦
* Returns as of 6 March 2025
More reading
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.
